-+ 0.00%
-+ 0.00%
-+ 0.00%

Adagene Completes Enrollment in Phase 2 Trial of Muzastotug-Keytruda Combination for Colorectal Cancer

PUBT·11/09/2026 12:04:52
Listen to the news
Adagene Completes Enrollment in Phase 2 Trial of Muzastotug-Keytruda Combination for Colorectal Cancer
  • Adagene completed enrollment of 60 patients in a randomized Phase 2 trial of muzastotug combined with Merck's Keytruda.
  • The trial compares dosing regimens in patients with previously treated microsatellite-stable colorectal cancer without liver metastases.
  • Initial results are expected in the first half of 2027 to guide dosing for a Phase 3 trial focused on overall survival.
  • Worldwide commercial rights to muzastotug remain with Adagene.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-124143), on November 09, 2026, and is solely responsible for the information contained therein.